All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...
IN8bio (INAB) announced new clinical data from the ongoing Phase 1 investigator-sponsored trial of INB-100, an allogeneic gamma-delta T cell ...
Patients with childhood and young adult cancer have an increased long-term risk for diabetes, noted as early as 10 years ...
Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...
Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.
A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...
The Metachromatic Leukodystrophy Initiative (MLDi) critically responds to the findings of Zhang et al. on lentivirus-modified ...
Fanconi anemia (FA) is a rare genetic disorder characterized by defective DNA repair, leading to hematopoietic stem cell (HSC) dysfunction and bone marrow failure. Replication stress, which ...
Hematopoietic stem cell transplantation (HSCT) is a vital treatment for both malignant and non-malignant disorders in pediatric patients.
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback